Chronic Sinusitis, Pediatric Cancer
Conditions
Keywords
Post-treatment chronic sinusitis, Pediatric cancer, Sinusitis, Quality of life
Brief summary
Chronic rhinosinusitis (CRS) is a frequent complication of facial cancer treatment, mainly related to radiotherapy. However, while radiological involvement is frequent, clinical expression seems less important. Few studies have investigated the incidence of this condition in the pediatric population while its evolution seems to be very chronic even if a partial improvement may occur with time. Our objective is therefore to study the impact of CSR in children treated for cancer of the cervicofacial region, to evaluate its incidence and medium-term evolution in order to determine whether it is necessary to set up a specific follow-up in these patients. The clinical impact of CSR is assessed by a specific SNOT 22 questionnaire in children treated for a head-neck mesenchymal malignancy in comparison with a control population consisting of children treated for a mesenchymal malignancy of non-head-neck location.
Interventions
OTHERSNOT 22 questionnaire
22 items, score between 0 and 5; sum, minimum = 0, maximum = 110; higher score = higher impact on quality of life)
Sponsors
University Hospital, Lille
Centre Oscar Lambret
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Inclusion criteria
* Study population: all patients under 18 years of age managed for a head neck mesenchymal cancer between January 1, 2018 and December 31, 2024 * Control population: all patient under 1 years of age managed for non -head neck mesenchymal cancer between January 1, 2018 and December 31, 2024
Exclusion criteria
* Patients with hematological tumors; * Patients with mucociliary pathologies or proven allergic rhinitis before the diagnosis of cancer * Patients who have required surgical treatment that has removed more than half of the sinus cavities * Tumor recurrence at the time of inclusion * Sinus surgery between the last radiological check-up and inclusion * Administrative reasons: inability to receive informed information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Impact of CRS in pediatric patients by Sino-Nasal Outcome Test-22 (SNOT 22) | >1 year to <4 years after the end of oncologic treatment |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of CRS in pediatric patients after head neck mesenchymal cancer management | 1 year after the end of the oncologic treatment |
| Correlation between SNOT 22 and clinical assessment by PADORES score | >1 year to <4 years after the end of oncologic treatment |
| Correlation between SNOT 22 and clinical assessment by lund-kennedy score | >1 year to <4 years after the end of oncologic treatment |
| Correlation between SNOT 22 and radiological assessment by Lund-Mackay score | >1 year to <4 years after the end of oncologic treatment |
| Radiological evolution of CRS by Lund-Mackay score | >1 year to <4 years after the end of oncologic treatment |
Contacts
PRINCIPAL_INVESTIGATORPierre Fayoux, MD,PhD
University Hospital, Lille
Outcome results
None listed